Intera Oncology® Inc., manufacturer of the only FDA-approved pump for Hepatic Artery Infusion (HAI) therapy for the treatment of intrahepatic cholangiocarcinoma (bile duct cancer confined to the liver) and colorectal cancer liver metastases, will showcase its Intera 3000 HAI pump as a sponsor of the 10th annual Cholangiocarcinoma Foundation Conference April 12 to 15 in Salt Lake City, Utah.

Intera Oncology® Inc., the manufacturer of the only FDA-approved implantable pump used for hepatic artery infusion (HAI) therapy, will showcase its Intera 3000 HAI Pump at the 2023 ASCO Gastrointestinal Cancer Symposium, taking place at the Moscone West in San Francisco, Calif. from January 19 to 20, 2023.

Intera Oncology is proud to announce that the FDA has approved the manufacture of the Intera 3000 Hepatic Arterial Infusion (HAI) Pump for HAI therapy for patients with colorectal cancer and cholangiocarcinoma. The Intera 3000 is now the only FDA-approved pump for HAI. “We formed Intera Oncology to bring this pump back to market after it was discontinued by another company. We could not let those who stood to benefit from HAI therapy go without that option,” said Michael Gaisford, president and CEO of Intera Oncology. “We are thrilled that we have accomplished our mission and that HAI therapy will be available to those who need it.”